AP
ANIP icon

Advisors Preferred’s ANI Pharmaceuticals ANIP Stock Holding History

Advisors Preferred’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-320
Closed -$6K – 340
2013
Q4 		$6K Buy
+320
New +$4.15K ﹤0.01% 338

Other funds holding ANIP

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.71B AUM 65.19% 1-Year Est. Return
FIM
Foresters Investment Management New York $5.05B AUM 5.06% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Advisors Preferred's ANIP Position: Q1 2014 in Review

Advisors Preferred sold out of ANI Pharmaceuticals (ANIP) in Q1 2014, closing a stake of 320 shares — an estimated $6K sold.

Advisors Preferred first reported a position in ANIP in Q4 2013 and held it in 1 quarter. The position peaked at $6K in Q4 2013. 67 funds tracked by Wall St. Rank hold ANIP as of Q1 2014.

  • Advisors Preferred reported no remaining ANI Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Advisors Preferred sold 320 ANI Pharmaceuticals shares in Q1 2014, an estimated $6K.
  • Advisors Preferred first reported a position in ANI Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Advisors Preferred's ANI Pharmaceuticals position peaked at $6K in Q4 2013.
  • 67 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2014.

Based on Advisors Preferred's 13F filing for Q1 2014, filed 14 May 2014.